Forgot your password?

Forgot your username?

database > company
Histogenics, Inc
Medical Devices & Tech
830 Winter Street, 3rd Floor
Waltham, MA 02451 USA
phone:
fax:
Symbol Private
Founded 2001
Employees 25
www.histogenics.com
Research Sector Medical Devices & Tech
Summary Description
Autologous neocartilage for tissue repair
Management
Patrick T. O'Donnell, President and Chief Executive Officer; Kevin McArdle, Chief Financial Officer; Laurence Berlowitz Tarrant, Ph.D., Chief Scientific Officer and Founder; Brian Callahan, Executive Vice-President of Clinical, Regulatory & Quality; Kirk Andriano, V.P. of Research and Development; Peter Hamilton, V.P. of Manufacturing & Production
Keywords
Regenerative Medicine, Orthopaedics, Sports Medicine, soft-tissue, repair, Cartilage Defects, Joint Repair, Knee Injuries

Comment | Printable Version | Modify profile |
Updated: May 02, 2012

Description
Histogenics is a late-stage, privately held regenerative medicine company located in Waltham, Massachusetts. The company combines cell therapy and tissue engineering technologies to develop innovative products for tissue repair and regeneration. The Company's flagship products focus on the treatment of patients with active lifestyles who suffer from articular cartilage-derived pain and immobility. Damaged cartilage cannot repair or restore itself, and if left untreated, can lead to chronic conditions such as osteoarthritis. The Company's product NeoCart®, developed for regeneration of full thickness cartilage lesions, consists of autologous engineered neocartilage that is grown ex vivo using the patient's own cells. The discrete three-dimensional piece of neocartilage tissue, having the characteristics of maturing native articular cartilage, is implanted into the defect, where it integrates with surrounding host tissue. NeoCart's Phase II data demonstrates clear superiority to microfracture procedures with no adverse events. NeoCart® is currently enrolling in a multi-center Phase III clinical study. Histogenics has also developed VeriCart™, a single step cell-free three-dimensional, collagen scaffold that requires no harvest of cartilage cells. VeriCart™ could be used with autologous stem cells or to augment microfracture procedures. Once implanted, the VeriCart™ scaffold attracts chondrocytes and stem cells into the scaffold to repair cartilage defects.
Products / Services
Histogenics products use the patient's own cells to grow articular cartilage. NeoCart® is a three-dimensional, neocartilage implant grown from patient's cells (chondrocytes) outside the body. At implantation in the patient, the cells have produced a hyaline cartilage-like matrix and there are still actively dividing cells which allow integration with the surrounding tissue. The VeriCart? matrix will augment microfracture procedures to allows cartilage cells to grow within its micropores at the site of the damage, either from the patient's chondrocytes or mesenchymal stem cells added to the matrix.
Technology / Differentiation
- Type I collagen scaffolds and hyaluronic acid/fibrin scaffolds for soft tissue regeneration - Fibroblast Growth Factor variants for therapeutic or reagent (cell culture) applications - Collagen-based bioadhesive for tissue attachment and approximation.
Market / Customers
650,000 procedures for cartilaginous injuries are performed each year. The company's products can significantly contribute to the $2 billion tissue engineered orthopedics (orthobiologics) market. The sports medicine market, which includes soft tissue injury, is continually driven by the increase in activity level among the baby boomer generation and younger adults. Orthobiologics, tissue engineering and regenerative medicine account for approximately 10 percent of the sports medicine market.
Competitors / Substitutes / Alternatives
Genzyme, Johnson & Johnson, Tigenix, ISTO
Strategy
The Company will continue towards completion of their NeoCart Phase III IND multicenter, randomized NeoCart® cartilage regeneration clinical study.The Company was provided a Special Protocol Assessment (SPA) by the FDA. Additionally, the Company will advance their clinical initiatives for the VeriCart? Single Step cell-free scaffold to augment the large microfracture procedure market.